论文部分内容阅读
目的观察氨氯地平联合氯沙坦治疗2型糖尿病肾病(T2DN)合并高血压的临床效果。方法选取2012年10月—2016年10月许昌市第二人民医院收治的144例T2DN合并高血压患者,使用随机数表法分为两组,各72例。两组入院后均接受糖尿病、高血压常规治疗,给予对照组氨氯地平,观察组在对照组基础上联合使用氯沙坦,对比两组治疗12周后血压、尿微量白蛋白(m Alb)、血肌酐(SCr)及尿白蛋白排泄率(UAER)。结果治疗后观察组收缩压(SBP)为(132.63±6.48)mm Hg,舒张压(DBP)为(79.03±4.32)mm Hg,较本组治疗前改善,且改善幅度明显优于对照组,差异有统计学意义(P<0.05);治疗前两组肾功能指标m Alb、SCr、UAER水平对比,差异无统计学意义(P>0.05),治疗后观察组下降幅度优于对照组,差异有统计学意义(P<0.05)。结论 2型糖尿病肾病合并高血压患者接受氨氯地平联合氯沙坦治疗可有效降低血压,减少蛋白尿生成,肾功能保护作用显著。
Objective To observe the clinical effect of amlodipine plus losartan in the treatment of type 2 diabetic nephropathy (T2DN) with hypertension. Methods A total of 144 T2DM patients with hypertension complicated with hypertension admitted to the Second People’s Hospital of Xuchang City from October 2012 to October 2016 were randomly divided into two groups (n = 72). After admission, both groups received conventional therapy of diabetes mellitus and hypertension, and received amlodipine in the control group. Losartan was used in the observation group on the basis of the control group. Blood pressure and urinary albumin (Alb) , Serum creatinine (SCr) and urinary albumin excretion rate (UAER). Results After treatment, SBP was (132.63 ± 6.48) mm Hg and the mean diastolic blood pressure (DBP) was (79.03 ± 4.32) mm Hg in the observation group, which was significantly better than that of the control group before treatment (P <0.05). There was no significant difference in the levels of m Alb, SCr and UAER between the two groups before treatment (P> 0.05). After treatment, the decreasing rate of the observation group was better than that of the control group Statistical significance (P <0.05). Conclusions Amlodipine combined with losartan in patients with type 2 diabetic nephropathy complicated with hypertension can effectively reduce blood pressure, reduce proteinuria, and protect renal function.